We are pleased to announce that Ontario Drug Benefit (ODB) has listed Afinitor (everolimus) for the treatment of patients with GI/Lung NET, effective November 20, 2017 through the Exceptional Access [...]
On Friday, November 10th, 2017 – World NET Cancer Day, businesses and coffee shops around the world raised awareness about NETs using special coffee cups designed for the day. CNETS [...]
The Gallium 68 scan, used with functional PET imaging, is a nuclear medicine scan that relies on the over-expression of somatostatin receptors to visualize tumours. NETs typically express several somatostatin receptor subtypes in [...]
As we advised previously, in July of this year the Manitoba government issued a bulletin http://www.gov.mb.ca/health/mdbif/…/bulletins/bulletin93.pdf that indicated a change in the listing for Somatuline (from 1 to 3 and no access [...]
Caprelsa is indicated for the treatment of symptomatic or progressive medullary thyroid cancer (MTC) in adult patients with unresectable locally advanced or metastatic disease. An application for this drug was [...]
Afinitor is currently paid for by provincial drug plans for patients with well-or moderately differentiated neuroendocrine tumours of pancreatic origin (pNET), in patients with unresectable, locally advanced or metastatic disease. [...]
It is with profound sadness that we share the news of the passing of Dr. Suzanne Richter, Medical Oncologist on the NET team at London Health Sciences Centre. This is [...]
CCO to provide Ga-Octreotate to Ontario patients free of charge in Sherbrooke A message from Helena Senta: “At this time, CCO is proceeding with PET scan approval for the [...]
Thank you to all our donors and volunteers! As we start anew into 2017, CNETS Canada would like to acknowledge and thank all our donors and volunteers for their generosity. [...]